Bremelanotide (Vyleesi) Off-Label Uses With Evidence Levels

How Bremelanotide Works: The Melanocortin Mechanism

Bremelanotide is a synthetic cyclic peptide that activates melanocortin receptors, primarily MC4R, in the hypothalamus and limbic system. Unlike phosphodiesterase-5 inhibitors such as sildenafil, which act on peripheral blood flow, bremelanotide modulates sexual desire through central nervous system pathways involving dopamine and oxytocin signaling. This distinction matters. It means the drug targets motivation and arousal at a neurological level rather than targeting genital hemodynamics alone.

The melanocortin system regulates a wide array of physiological processes: energy homeostasis, inflammation, cardiovascular function, and pigmentation 1. Bremelanotide's parent compound, melanotan II, was originally studied as a sunless tanning agent in the 1990s at the University of Arizona. Researchers noticed a striking side effect: spontaneous erections in male volunteers. That observation launched two decades of sexual medicine research 2.

MC4R activation in the paraventricular nucleus triggers downstream release of oxytocin, which projects to spinal cord autonomic centers controlling genital arousal 3. Because the same receptor mediates appetite suppression and energy expenditure, bremelanotide has also attracted interest as an anti-obesity agent. The breadth of MC4R signaling explains why this single molecule has been studied across such different clinical contexts.

On-Label Foundation: The RECONNECT Trials

Before evaluating off-label uses, the approved indication deserves context. The FDA approved bremelanotide in June 2019 based on the RECONNECT program, consisting of two randomized, double-blind, placebo-controlled Phase III trials enrolling 1,247 premenopausal women with acquired, generalized HSDD 4.

Over 24 weeks, women using bremelanotide 1.75 mg subcutaneously as needed showed a statistically significant increase in desire (measured by the Female Sexual Function Index desire domain) and a reduction in distress (measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm). The co-primary endpoints both reached significance: FSFI desire score increased by 0.5 points over placebo, and FSDS-DAO decreased by 0.7 points over placebo.

Nausea was the most common reason for discontinuation, occurring in approximately 40% of bremelanotide-treated patients versus 1% on placebo. About 13% of women who experienced nausea found it severe enough to stop treatment 4. The FDA label restricts use to premenopausal women and recommends against use in patients with uncontrolled hypertension or cardiovascular disease due to transient increases in systolic blood pressure (mean increase of 6 mmHg) observed within 12 hours of dosing 5.

Off-Label Use 1: Male Erectile Dysfunction (Phase II Evidence)

The strongest off-label evidence exists for erectile dysfunction in men. Three published clinical trials have evaluated bremelanotide (or its predecessor melanotan II) for this indication.

A 2000 proof-of-concept study by Wessells et al. tested subcutaneous melanotan II in 10 men with psychogenic or organic ED. Eight of 10 participants developed clinically significant erections as measured by RigiScan monitoring. The effect was dose-dependent, with higher responses at the 0.025 mg/kg dose 2.

A larger Phase IIb trial published in 2008 enrolled 342 men with ED and randomized them to bremelanotide (various doses administered intranasally) or placebo 6. The study showed significant improvements in erectile function via the International Index of Erectile Function (IIEF). Successful intercourse attempts increased from 33.7% on placebo to 50.4% on the highest bremelanotide dose. The intranasal formulation was later abandoned after the FDA raised concerns about blood pressure effects.

A 2005 at-home study of bremelanotide in 48 men with ED demonstrated that 68% of dose administrations resulted in erections sufficient for intercourse, versus 23% with placebo, as measured by patient diaries 7.

Evidence level: Phase IIb. No Phase III trial in men has been completed. The intranasal formulation was placed on clinical hold by the FDA in 2007 due to blood pressure concerns, which shifted development toward the subcutaneous route and the female HSDD indication.

Prescribers considering off-label use in men should be aware that no dose-finding study of the subcutaneous 1.75 mg formulation has been published for male ED specifically. The pharmacokinetic profile may differ between men and women, and the optimal male dose remains unestablished.

Off-Label Use 2: Postmenopausal HSDD (Phase II/III Pooled Data)

The RECONNECT trials excluded postmenopausal women, leaving a significant clinical gap. A pooled analysis of Phase II and early Phase III data, however, included some naturally postmenopausal women not on hormone therapy.

Palatin Technologies reported in 2017 that a subset of postmenopausal women (n=217 across studies) showed improvements in desire scores comparable to those seen in the premenopausal population 8. The FSFI desire domain improvement and FSDS-DAO reduction both trended in the same direction, though the postmenopausal subset was not independently powered for statistical significance.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction acknowledged the unmet need in postmenopausal HSDD but did not recommend bremelanotide for this population due to insufficient standalone evidence 9. The North American Menopause Society (NAMS) 2024 position statement similarly noted that "bremelanotide has not been adequately studied in postmenopausal women to support a recommendation" 10.

Evidence level: Exploratory/pooled. No dedicated Phase III trial in postmenopausal women has been initiated as of May 2026.

Several telehealth clinics prescribe bremelanotide off-label for postmenopausal patients who have failed or declined flibanserin. Clinicians doing so should document the rationale, counsel patients on the limited evidence base, and monitor blood pressure given the older demographic's higher cardiovascular baseline risk.

Off-Label Use 3: Female Arousal Disorder Without Low Desire

The RECONNECT trials required a diagnosis of HSDD (low desire plus distress). Women with isolated arousal disorder or orgasmic disorder were excluded. Preclinical data suggest bremelanotide's MC4R-mediated oxytocin release could improve physiological arousal independently of desire 3.

A small open-label pilot (n=18) published in 2004 evaluated bremelanotide in women with female sexual arousal disorder (FSAD). Genital blood flow, measured by vaginal photoplethysmography, increased significantly after bremelanotide administration compared to baseline. Subjective arousal ratings also improved 11.

Evidence level: Pilot/open-label only. No randomized controlled trial has isolated arousal disorder as the primary endpoint for bremelanotide.

Off-Label Use 4: Obesity and Appetite Suppression

MC4R is a well-established regulator of energy balance. Loss-of-function mutations in MC4R cause the most common monogenic form of obesity, accounting for approximately 2-5% of severe early-onset obesity cases 12. Setmelanotide, a selective MC4R agonist, is FDA-approved for obesity caused by POMC, PCSK1, or LEPR deficiency, confirming the pathway's clinical relevance.

Bremelanotide is less selective than setmelanotide, activating MC1R, MC3R, and MC5R in addition to MC4R 1. In preclinical rodent models, bremelanotide reduced food intake and body weight in a dose-dependent fashion. A small Phase I/II study noted that bremelanotide-treated subjects experienced transient appetite suppression and mild weight loss over 12 weeks, though this was not a primary endpoint 13.

In the RECONNECT trials, weight change was not systematically reported as a secondary endpoint. Post-hoc analysis did not show significant mean weight differences between the bremelanotide and placebo groups over 24 weeks, suggesting that as-needed dosing (versus daily administration) may be insufficient to drive meaningful metabolic effects 4.

Evidence level: Preclinical plus incidental Phase I/II observations. No obesity-focused clinical trial of bremelanotide is currently registered on ClinicalTrials.gov. The market is dominated by GLP-1 receptor agonists with far superior efficacy data.

Off-Label Use 5: Skin Pigmentation and Tanning

Bremelanotide's MC1R activity stimulates melanogenesis. Its precursor, melanotan II, was originally developed for photoprotective tanning, and illicit "melanotan" peptides remain widely sold online for cosmetic darkening 14.

A Phase I study of intranasal bremelanotide found dose-dependent facial skin darkening in fair-skinned subjects, measured by reflectance spectrophotometry 15. This pigmentation effect was considered a side effect rather than a therapeutic goal in the sexual medicine program.

Theoretical interest exists in using melanocortin agonists for vitiligo repigmentation and erythropoietic protoporphyria (EPP). Afamelanotide (Scenesse), an MC1R-selective agonist, is FDA-approved for EPP. Bremelanotide's broader receptor profile makes it a suboptimal choice for pigmentation disorders compared to more selective agents.

Evidence level: Phase I (incidental finding). No clinical development program for dermatological indications exists. Unregulated use of research-grade melanotan peptides carries risks of contamination, melanocyte activation in nevi, and unpredictable dosing.

Off-Label Use 6: Hemorrhagic Shock and Organ Protection

An early and largely forgotten area of bremelanotide research involves hemorrhagic shock. MC3R and MC4R activation trigger anti-inflammatory cascades through the cholinergic anti-inflammatory pathway. Animal studies in the early 2000s demonstrated that melanocortin agonists reduced organ damage and improved survival in rat models of hemorrhagic shock and ischemia-reperfusion injury 16.

These findings have not advanced beyond preclinical models for bremelanotide specifically. The mechanism remains of academic interest, and other melanocortin peptides (notably ACTH analogs) have been explored in small human trials for acute inflammatory states. No human trial of bremelanotide for shock resuscitation has been conducted.

Evidence level: Preclinical only.

Safety Considerations Across Off-Label Contexts

Several safety signals deserve attention regardless of indication.

Blood pressure. Bremelanotide causes a transient mean increase of approximately 6 mmHg systolic and 3 mmHg diastolic, peaking 2-3 hours post-dose and resolving within 12 hours 5. In men with pre-existing hypertension (a population not well-studied), this effect could carry higher risk. The FDA label contraindicates use in patients with uncontrolled hypertension.

Nausea. The 40% nausea rate observed in RECONNECT may differ in male or postmenopausal populations but should be assumed until disproven. Pre-treatment with ondansetron has been suggested anecdotally by prescribers but lacks formal study 4.

Hyperpigmentation. Focal skin darkening, particularly on the face and gums, has been reported with repeated dosing. The clinical significance is unclear, but patients with a history of melanoma should avoid the drug given MC1R's role in melanocyte proliferation 14.

Drug interactions. Bremelanotide slows gastric emptying. The FDA label warns against co-administration with oral naltrexone, as bremelanotide reduced naltrexone Cmax by 47% and AUC by 21% 5. This interaction could be relevant for patients on naltrexone-bupropion (Contrave) for weight management.

Evidence Summary Table

| Indication | Highest Trial Phase | Sample Size | Key Finding | Guideline Support | |---|---|---|---|---| | Premenopausal HSDD (on-label) | Phase III | N=1,247 | Co-primary endpoints met | FDA-approved | | Male erectile dysfunction | Phase IIb | N=342 | 50.4% vs 33.7% intercourse success | None | | Postmenopausal HSDD | Pooled Phase II/III subset | N=217 | Trends favor bremelanotide; underpowered | None (NAMS, Endocrine Society) | | Female arousal disorder | Open-label pilot | N=18 | Increased genital blood flow | None | | Obesity | Phase I (incidental) | Small | Transient appetite suppression | None | | Skin pigmentation | Phase I (incidental) | Small | Dose-dependent darkening | None | | Hemorrhagic shock | Preclinical | Animal models | Reduced organ injury in rats | None |

Any off-label prescribing of bremelanotide should be documented with clear clinical rationale, patient consent acknowledging limited evidence, and a monitoring plan that includes blood pressure checks at baseline and within 2 hours of the first dose.